RCT GTPS: Evaluation of TENEX for Greater Trochanteric Pain Syndrome (GTPS)

Sponsor
Montefiore Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05710627
Collaborator
(none)
117
1
2
12
9.7

Study Details

Study Description

Brief Summary

The aim of this study is to characterize the efficacy of percutaneous tenotomy (PUT) using TENEX®, a device used for the treatment of various tendinopathies. In this study an ultrasound (US) is performed to guide the partial release of gluteus medius and minimus and Iliotibial band tendons in patients diagnosed with refractory Greater Trochanteric Pain Syndrome (GTPS) vs control.

The study team hypothesizes that PUT can improve the pain level and function for individuals suffering with GTPS. The study will assess walking, standing, and side-lying tolerance, as well as medication utilization. The investigator team predicts that this percutaneous outpatient procedure can decrease pain and medication utilization while increasing mobility.

Condition or Disease Intervention/Treatment Phase
  • Device: TENEX
N/A

Detailed Description

Greater trochanteric pain syndrome (GTPS) is one of the most common causes of lateral hip pain in adults. GTPS is repetitive overload tendinopathy of the gluteus medius (GMed) and Iliotibial band (ITB), which play a primary role in hip abduction and pelvic stabilization in walking, stair climbing, running and standing on one leg. It is thought that the core pathology is greater trochanteric bursitis (TB) with or without coexisting gluteal tendinopathy. Some common etiologies include prolonged excessive pressure to the area, injury to the side of the hip, and repetitive movements; however, local steroid injections to the greater TB are not often successful over the long-term. The best estimates of prevalence are from a large, community-based study with over 3000 adults aged 50 to 70 years, in which unilateral GTPS was present in 15 percent of women and 6.6 percent of men. Patients who have not improved after at least 12 months of conservative medical management (CMM), including physical therapy, oral medications, or a local steroid injection have no other conservative treatment recourse. Open surgery for GMed or ITB tears is not recommended unless a tear is diagnosed on MRI. Based on a published study, a 60% improvement was shown in pain with the performance of TENEX of the GMed.

The purpose of this project is to study the outcome of GMed and ITB PUT on CMM refractory GTPS. We want to quantify and show the scales of the pain in pre-operative and post-treatment cases. We also want to see how effective the surgery is in specific terms of pain levels because GTPS is a pain syndrome and reduction in pain level is the most important clinical factor.

Patient Reported Outcome Measure (PROM) is one of the main outcomes that medical research is validated with and through this study we want to show the most important outcome of GTPS i.e., pain level (PROM for GTPS). Previous studies which focused on surgical outcomes have been mostly single-center trials.

Pain and mobility impact patients' Quality of Life (QoL) and medical cost burden due to unemployment, psychosocial well-being, and functional dependence. The standard of care offered to address the pain and mobility needs of those with GTPS is to provide CMM, followed by open or arthroscopic surgery if surgery is indicated. However, there is a treatment gap for those patients who have failed CMM and are not surgical candidates. The authors submit that TENEX of the GMed and ITB may address this gap. The results from this research may have broad impacts on the treatment algorithm for patients with GTPS.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
117 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Percutaneous Tenotomy of the Gluteus Medius and Iliotibial Band for Greater Trochanteric Pain Syndrome (GTPS): A Randomized Clinical Trial
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

Standard of care

Experimental: Treatment

TENEX device will be used

Device: TENEX
Use of TENEX device for sectioning of the gluteus medius and ITB tendons.

Outcome Measures

Primary Outcome Measures

  1. Pain Level [Baseline (before the procedure)]

    The difference in pain levels in patients before and after the procedure. Pain levels (NRS scale) recorded in the pre-operative visit will be compared to the pain levels at FU visits. Numeric rating scale(NRS) is a pain screening tool used to assess pain severity using a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable.

  2. Pain Level [1-month]

    The difference in pain levels in patients before and after the procedure. Pain levels (NRS scale) recorded in the pre-operative visit will be compared to the pain levels at FU visits. Numeric rating scale(NRS) is a pain screening tool used to assess pain severity using a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable.

  3. Pain Level [3-month]

    The difference in pain levels in patients before and after the procedure. Pain levels (NRS scale) recorded in the pre-operative visit will be compared to the pain levels at FU visits. Numeric rating scale(NRS) is a pain screening tool used to assess pain severity using a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable.

  4. Pain Level [6-month]

    The difference in pain levels in patients before and after the procedure. Pain levels (NRS scale) recorded in the pre-operative visit will be compared to the pain levels at FU visits. Numeric rating scale(NRS) is a pain screening tool used to assess pain severity using a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable.

  5. Pain Level [12-month]

    The difference in pain levels in patients before and after the procedure. Pain levels (NRS scale) recorded in the pre-operative visit will be compared to the pain levels at FU visits. Numeric rating scale(NRS) is a pain screening tool used to assess pain severity using a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable.

Secondary Outcome Measures

  1. EQ-5D-5L [Baseline (before the procedure)]

    In this study, we will also explore a comparative analysis between TENEX to conventional medical treatments. The study team will compare quality of life using the EQ-5D-5L. Walking, side-lying, sit-to-stand transfers, and medication utilization will be assessed as well. EQ-5D-5L is the descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1- digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a five digit number that describes the patient's health state.

  2. EQ-5D-5L [1-month]

    In this study, we will also explore a comparative analysis between TENEX to conventional medical treatments. The study team will compare quality of life using the EQ-5D-5L. Walking, side-lying, sit-to-stand transfers, and medication utilization will be assessed as well. EQ-5D-5L is the descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1- digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a five digit number that describes the patient's health state.

  3. EQ-5D-5L [3-month]

    In this study, we will also explore a comparative analysis between TENEX to conventional medical treatments. The study team will compare quality of life using the EQ-5D-5L. Walking, side-lying, sit-to-stand transfers, and medication utilization will be assessed as well. EQ-5D-5L is the descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1- digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a five digit number that describes the patient's health state.

  4. EQ-5D-5L [6-month]

    In this study, we will also explore a comparative analysis between TENEX to conventional medical treatments. The study team will compare quality of life using the EQ-5D-5L. Walking, side-lying, sit-to-stand transfers, and medication utilization will be assessed as well. EQ-5D-5L is the descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1- digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a five digit number that describes the patient's health state.

  5. EQ-5D-5L [12-month]

    In this study, we will also explore a comparative analysis between TENEX to conventional medical treatments. The study team will compare quality of life using the EQ-5D-5L. Walking, side-lying, sit-to-stand transfers, and medication utilization will be assessed as well. EQ-5D-5L is the descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1- digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a five digit number that describes the patient's health state.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 18-90

  • People with GTPS of all different levels and etiologies confirmed with MRI or CT scan

  • Ability to give informed consent forms independently

  • Failed conservative medical treatment for at least 6 months

Exclusion Criteria:
  • Significant mobility restrictions; people using wheelchairs

  • Previous surgery to the GMed or ITB

Contacts and Locations

Locations

Site City State Country Postal Code
1 Montefiore Medical Center Bronx New York United States 10461

Sponsors and Collaborators

  • Montefiore Medical Center

Investigators

  • Principal Investigator: Sayed E. Wahezi, MD, Montefiore Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sayed Wahezi, Program Director, Montefiore Medical Center
ClinicalTrials.gov Identifier:
NCT05710627
Other Study ID Numbers:
  • 2022-14588
First Posted:
Feb 2, 2023
Last Update Posted:
Feb 2, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 2, 2023